CN102276496A - 乙酰谷酰胺化合物及其药物组合物 - Google Patents
乙酰谷酰胺化合物及其药物组合物 Download PDFInfo
- Publication number
- CN102276496A CN102276496A CN 201110214372 CN201110214372A CN102276496A CN 102276496 A CN102276496 A CN 102276496A CN 201110214372 CN201110214372 CN 201110214372 CN 201110214372 A CN201110214372 A CN 201110214372A CN 102276496 A CN102276496 A CN 102276496A
- Authority
- CN
- China
- Prior art keywords
- aceglutamide
- freeze
- injection
- drying
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005488 aceglutamide Drugs 0.000 title claims abstract description 168
- -1 Aceglutamide compound Chemical class 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 claims abstract description 59
- 239000000843 powder Substances 0.000 claims abstract description 48
- 238000002347 injection Methods 0.000 claims abstract description 41
- 239000007924 injection Substances 0.000 claims abstract description 41
- 238000009472 formulation Methods 0.000 claims abstract description 35
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 10
- 229910017488 Cu K Inorganic materials 0.000 claims abstract description 9
- 229910017541 Cu-K Inorganic materials 0.000 claims abstract description 9
- 239000002245 particle Substances 0.000 claims abstract description 9
- 239000013078 crystal Substances 0.000 claims abstract description 5
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 claims description 93
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 86
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- 239000000243 solution Substances 0.000 claims description 61
- 239000003795 chemical substances by application Substances 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 238000003756 stirring Methods 0.000 claims description 40
- 238000001914 filtration Methods 0.000 claims description 35
- 230000003750 conditioning effect Effects 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 238000004108 freeze drying Methods 0.000 claims description 26
- 239000000725 suspension Substances 0.000 claims description 24
- 239000008227 sterile water for injection Substances 0.000 claims description 22
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 238000001035 drying Methods 0.000 claims description 17
- 230000001105 regulatory effect Effects 0.000 claims description 17
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
- 238000005261 decarburization Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 238000012856 packing Methods 0.000 claims description 15
- 238000009413 insulation Methods 0.000 claims description 14
- 238000010792 warming Methods 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 230000005260 alpha ray Effects 0.000 claims description 8
- 229940125904 compound 1 Drugs 0.000 claims description 8
- 239000012065 filter cake Substances 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000000859 sublimation Methods 0.000 claims description 7
- 230000008022 sublimation Effects 0.000 claims description 7
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 5
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 claims description 5
- 239000001509 sodium citrate Substances 0.000 claims description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 235000017550 sodium carbonate Nutrition 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 15
- 230000008901 benefit Effects 0.000 abstract description 7
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 239000003610 charcoal Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000005352 clarification Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000000274 adsorptive effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 3
- 238000011082 depyrogenation Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010059411 Prolonged expiration Diseases 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 229940087511 calcium disodium versenate Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000009775 high-speed stirring Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
处方编号 | 1 | 2 | 3 | 4 |
回收率(%) | 99.8 | 99.2 | 99.3 | 91.2 |
澄明度 | 无色、澄清 | 无色、澄清 | 无色、澄清 | 无色、澄清 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110214372A CN102276496B (zh) | 2011-07-28 | 2011-07-28 | 乙酰谷酰胺化合物及其药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110214372A CN102276496B (zh) | 2011-07-28 | 2011-07-28 | 乙酰谷酰胺化合物及其药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102276496A true CN102276496A (zh) | 2011-12-14 |
CN102276496B CN102276496B (zh) | 2012-07-04 |
Family
ID=45102286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110214372A Active CN102276496B (zh) | 2011-07-28 | 2011-07-28 | 乙酰谷酰胺化合物及其药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102276496B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716094A (zh) * | 2012-05-29 | 2012-10-10 | 海南卫康制药(潜山)有限公司 | 注射用甲磺酸培氟沙星冻干粉组合物及其制备方法 |
CN103012192A (zh) * | 2013-01-10 | 2013-04-03 | 黄明芳 | 一种新型乙酰谷酰胺化合物及其药物组合物 |
CN104434819A (zh) * | 2014-11-15 | 2015-03-25 | 成都天台山制药有限公司 | 注射用乙酰谷酰胺粉针剂药物组合物和制法 |
CN105037195A (zh) * | 2015-06-26 | 2015-11-11 | 康普药业股份有限公司 | 乙酰谷酰胺及其注射液与制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5350394A (en) * | 1976-10-20 | 1978-05-08 | Kyowa Hakko Kogyo Co Ltd | Preparation of n-acetyl-l-glutamine by culture method |
CN101434559A (zh) * | 2008-12-12 | 2009-05-20 | 上海朝晖药业有限公司 | 乙酰谷酰胺的制备方法 |
CN101468955A (zh) * | 2008-07-24 | 2009-07-01 | 宁波市镇海海德生化科技有限公司 | 一种n-乙酰-l-谷氨酰胺的生产方法 |
-
2011
- 2011-07-28 CN CN201110214372A patent/CN102276496B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5350394A (en) * | 1976-10-20 | 1978-05-08 | Kyowa Hakko Kogyo Co Ltd | Preparation of n-acetyl-l-glutamine by culture method |
CN101468955A (zh) * | 2008-07-24 | 2009-07-01 | 宁波市镇海海德生化科技有限公司 | 一种n-乙酰-l-谷氨酰胺的生产方法 |
CN101434559A (zh) * | 2008-12-12 | 2009-05-20 | 上海朝晖药业有限公司 | 乙酰谷酰胺的制备方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102716094A (zh) * | 2012-05-29 | 2012-10-10 | 海南卫康制药(潜山)有限公司 | 注射用甲磺酸培氟沙星冻干粉组合物及其制备方法 |
CN103012192A (zh) * | 2013-01-10 | 2013-04-03 | 黄明芳 | 一种新型乙酰谷酰胺化合物及其药物组合物 |
CN104434819A (zh) * | 2014-11-15 | 2015-03-25 | 成都天台山制药有限公司 | 注射用乙酰谷酰胺粉针剂药物组合物和制法 |
CN104434819B (zh) * | 2014-11-15 | 2018-06-01 | 成都天台山制药有限公司 | 注射用乙酰谷酰胺粉针剂药物组合物和制法 |
CN105037195A (zh) * | 2015-06-26 | 2015-11-11 | 康普药业股份有限公司 | 乙酰谷酰胺及其注射液与制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102276496B (zh) | 2012-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103340895B (zh) | 一种含多种微量元素的组合物,其制剂及制备方法 | |
CN101411710B (zh) | 培美曲塞二钠冻干粉针剂及其制备方法 | |
CN102276496B (zh) | 乙酰谷酰胺化合物及其药物组合物 | |
CN102525963B (zh) | 一种硫酸奈替米星冻干粉针及其制备方法 | |
CN102276533B (zh) | 一种新的奥扎格雷钠化合物及其药物组合物 | |
CN102285970B (zh) | 一种埃索美拉唑化合物、制备方法及其药物组合物 | |
CN100998595B (zh) | 含有头孢特伦酯环糊精包合物的药物组合物及其制备方法 | |
CN102302461A (zh) | 一种注射用丹曲林钠冻干粉针剂及其制备方法 | |
CN104434819A (zh) | 注射用乙酰谷酰胺粉针剂药物组合物和制法 | |
CN101003540A (zh) | 一种抗感染化合物和用途 | |
CN112618496A (zh) | 一种注射用阿奇霉素冻干粉针剂的制备方法 | |
CN103110640B (zh) | 一种注射用头孢唑肟钠和复方氨基酸注射液的药物组合物 | |
CN102367229B (zh) | 一种二乙酰氨乙酸乙二胺化合物及其药物组合物 | |
CN101904862B (zh) | 注射用水溶性维生素组合物冻干制剂 | |
CN103494779B (zh) | 一种注射用炎琥宁粉针制剂及其制备方法 | |
CN101190214A (zh) | 紫杉醇注射液及其制备方法 | |
CN103980279A (zh) | 一种甲氨蝶呤化合物及注射用甲氨蝶呤 | |
CN104129803A (zh) | 稳定的硝普钠晶体化合物、其药物组合物及制备方法 | |
CN101152174B (zh) | 一种稳定的利福霉素钠注射液的处方及制备方法 | |
CN101491495B (zh) | 丹酚酸b镁注射剂、制备方法及应用 | |
CN110354068B (zh) | 一种以熊果酸/齐墩果酸为原料的超分子水凝胶、制备方法及应用 | |
CN103735522B (zh) | 一种炎琥宁冻干粉针及其制备方法 | |
CN1813713A (zh) | 溶液型炎琥宁注射剂及其制备方法 | |
CN103027894A (zh) | 注射用头孢他啶组合物及其制备方法 | |
CN1069826C (zh) | 盐酸丁卡因冻干粉针剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111214 Assignee: Kamp Pharmaceuticals Co., Ltd. Assignor: Zhou Xiaodong Contract record no.: 2013360000144 Denomination of invention: Novel aceglutamide compound and pharmaceutical composition thereof Granted publication date: 20120704 License type: Common License Record date: 20131009 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111214 Assignee: Kamp Pharmaceuticals Co., Ltd. Assignor: Zhou Xiaodong Contract record no.: 2015360000150 Denomination of invention: Novel aceglutamide compound and pharmaceutical composition thereof Granted publication date: 20120704 License type: Exclusive License Record date: 20151222 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Kamp Pharmaceuticals Co., Ltd. Assignor: Zhou Xiaodong Contract record no.: 2015360000150 Date of cancellation: 20180601 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Kamp Pharmaceuticals Co., Ltd. Assignor: Zhou Xiaodong Contract record no.: 2013360000144 Date of cancellation: 20180611 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20111214 Assignee: Kamp Pharmaceuticals Co., Ltd. Assignor: Zhou Xiaodong Contract record no.: 2018990000155 Denomination of invention: Novel aceglutamide compound and pharmaceutical composition thereof Granted publication date: 20120704 License type: Exclusive License Record date: 20180613 |
|
EE01 | Entry into force of recordation of patent licensing contract |